Skip to main content
BNC Korea Co, Ltd logo

BNC Korea Co, Ltd — Investor Relations & Filings

Ticker · 256840 ISIN · KR7256840000 KO Manufacturing
Open in API
Filings indexed 283 across all filing types
Latest filing 2022-12-14 Legal Proceedings Report
Country KR South Korea
Listing KO 256840

About BNC Korea Co, Ltd

http://www.bnckorea.co.kr

BNC Korea Co., Ltd. is a biomedical company established in 2007 that engages in the research, development, production, and sale of medical devices, pharmaceuticals, and biologicals. The company specializes in products derived from biomaterials, with a particular focus on hyaluronic acid. Its core product portfolio includes hyaluronic acid-based dermal fillers and botulinum toxin injectables for the medical aesthetics market. BNC Korea operates a GMP-certified facility for manufacturing cutting-edge drug substances and specialty medicines, aiming to develop strategic application products for next-generation bio markets.

Recent filings

Filing Released Lang Actions
기타경영사항(자율공시)(잠정 제조중지명령 및 회수폐기명령에 대한 집행정지 인용결정)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding a court decision on a temporary suspension of manufacturing and recall orders. It details legal proceedings (a court injunction) involving the company and a regulatory body (Daegu Regional Food and Drug Administration). Since it specifically addresses legal outcomes and regulatory actions, it falls under the 'Legal Proceedings Report' category.
2022-12-14 Korean
[기재정정]수시공시의무관련사항(공정공시)(비에녹스(BIENOX, 보툴리눔톡신) 공급계약 체결의 건)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (한국비엔씨) regarding a 'Fair Disclosure' (공정공시) update. It specifically details a correction (정정신고) to a previously announced supply contract for a product called 'BIENOX'. Since it is a formal regulatory disclosure regarding a business contract update and does not fit into specific categories like M&A or financial reports, it falls under the general regulatory filing category.
2022-12-13 Korean
기타경영사항(자율공시)(품목허가 취소 및 전 제조업무정지 6개월, 회수폐기명령, 회수사실 공표명령에 대한 집행정지 잠정처분 신청 인용 결정)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding a legal matter involving the company's product license and manufacturing suspension. It details a court's decision to grant a temporary injunction against administrative penalties imposed by the Ministry of Food and Drug Safety. Since this document pertains to significant legal proceedings and regulatory actions, it falls under the 'Legal Proceedings Report' category.
2022-12-12 Korean
투자판단관련주요경영사항(비에녹스주(클로스트리디움보툴리눔독소A형)(수출용) 품목허가 취소 행정처분 통지 및 회수폐기 명령)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure from a Korean company (한국비엔씨) regarding an administrative action (license cancellation and recall order) taken by the Ministry of Food and Drug Safety. It details the legal and operational impact of this regulatory action, including the company's plan to file for an injunction and lawsuit. Since this document describes significant legal and regulatory proceedings affecting the company's business operations, it falls under the 'Legal Proceedings Report' category.
2022-12-02 Korean
[기재정정]기타경영사항(자율공시)(잠정 제조중지 명령 및 회수폐기명령에 대한 집행정지 잠정처분 신청 인용결정 )
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean company (Korea BNC) regarding a legal proceeding involving a temporary suspension of manufacturing and a recall order from the Daegu Regional Food and Drug Administration. It details a court decision to extend the stay of execution for these administrative orders. Since this document pertains to significant legal and regulatory actions affecting the company's operations and does not fit into specific categories like M&A or financial reporting, it is classified as a Regulatory Filing (RNS).
2022-11-28 Korean
[기재정정]투자판단관련주요경영사항(코로나치료제로 임상중인 안트로퀴노놀의 라이센스계약체결)
M&A Activity Classification · 100% confidence The document is a regulatory filing from the Korean company '한국비엔씨' (Korea BNC) regarding a 'Correction Report' (정정신고) for a previously disclosed 'Major Management Matter' (주요경영사항). The content details a licensing agreement for a COVID-19 treatment (Antroquinonol) with Golden Biotechnology Corporation, including specific contract terms, milestones, and financial implications. Since this is a formal regulatory disclosure of a material business contract (M&A/Licensing activity) filed with a regulatory body, it falls under the 'Regulatory Filings' category as it does not fit into the specific definitions of M&A (which usually implies corporate mergers/acquisitions) or other specialized categories.
2022-11-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.